NCT07234162

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

A Phase 3, Open-Label, Randomized, Multinational Study to Investigate the Anti-tumor Efficacy of Golidocitinib Versus Investigator's Choice in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 218 (estimated)
• Sponsor: Dizal Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL). This study will treat patients with pathologically confirmed PTCL who have relapsed after or been refractory/intolerant to at least one prior systemic treatment regimen(s).

Conditions

• Peripheral T-cell Lymphoma

Interventions

Type	Name	Description
DRUG	Golidocitinib	150 mg, orally, once daily, with or without food, in a 21-day cycle
DRUG	Chidamide	30 mg, orally, twice a week, with an interval of no less than 3 days in a 21-day cycle
DRUG	Pralatrexate	30 mg/m2, intravenous push, once weekly for 6 weeks in 7-week cycles
DRUG	Gemcitabine	1000 mg/m2, intravenous infusion, administered on Day 1, Day 8 and Day 15 of a 28-day cycle
DRUG	Belinostat	1000 mg/m2, intravenous infusion, administered once daily (QD) on Day 1 to Day 5 of a 21-day cycle

Timeline

• Start date: 2024-05-13
• Primary completion: 2027-11-30
• Completion: 2028-10-31
• First posted: 2025-11-18
• Last updated: 2025-11-18

Locations

50 sites across 3 countries: China, Taiwan, Thailand